Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Is remdesivir now approved by the FDA for outpatient use?

Yes. Coverage for remdesivir has been evolving and changing quickly over the past few weeks.  Initially, CMS announced the creation of code J0248 (Injection, remdesivir, 1 mg) with an effective date of December 23, 2021. However, at the time the FDA had not yet updated its approval of VEKLURY to include outpatient usage. Meaning, although CMS had created a HCPCS code to report on outpatient claims, usage of the drug in the outpatient setting would have been considered “off-label usage.”  On January 7, 2022, CMS issued an MLN Connects Special Edition noting that that due to the lack of a national coverage determination for administration in an outpatient setting, Medicare coverage for VEKLURY (remdesivir) in an outpatient environment would be left to MAC discretion.

Most recently, on January 21, 2022, the FDA expanded the emergency use authorization (EUA) for remdesivir to include the use for non-hospitalized patients with mild to moderate COVID-19 who are at high risk of their case becoming severe.  Craneware will continue to monitor and update this site as information becomes available.

CMS MLN Connects dated January 7, 2022:
https://www.cms.gov/outreach-and-educationoutreachffsprovpartprogprovider-partnership-email-archive/2022-01-07-mlnc-se

EUA Fact Sheet for VEKLURY:
https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fact-sheet-for-hcps.pdf

Skip to toolbar